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SUMMARY
CD137, a potent costimulatory receptor for CD8+
T cells, is expressed in various non-T cells, but little
is known about its regulatory functions in these cells.
In this study, we show that CD137 signaling, specif-
ically in intestinal CD11bCD103+ dendritic cells
(DCs), restricts acute colitis progression. Mechanisti-
cally, CD137 engagement activates TAK1 and subse-
quently stimulates theAMPK-PGC-1aaxis to enhance
expression of the Aldh1a2 gene encoding the retinoic
acid (RA) metabolizing enzyme RALDH2. RA can act
on CD11b+CD103 DCs and induce SOCS3 expres-
sion, which, in turn, suppresses p38MAPK activation
and interleukin-23 (IL-23) production. Administration
of RA in DC-specific CD137/ mice represses IL-23-
producing CD11b+CD103 DCs and TH17 cells, indi-
cating that RA is a major inhibitory effector molecule
against intestinal CD11b+CD103 DCs. Additionally,
the therapeutic effect of the anti-CD137 antibody is
abrogated in DC-specific CD137/ mice. Taken
together, our results define a mechanism of paracrine
immunoregulation operating between adjacent DC
subsets in the intestine.
INTRODUCTION
CD137 (also known as 4-1BB and TNFRSF9) and its ligand,
CD137L (also called 4-1BBL or TNFSF9), are expressed on a
variety of hematopoietic and non-hematopoietic cells, where
their expression is mostly inducible (Lee and Croft, 2009). Early
studies showed that CD137 functions as a potent costimulatory
receptor for CD8+ T cells (Melero et al., 1997; Shuford et al.,
1997), but more recent reports have extended its functions
beyond lymphoid cells (Hsieh et al., 2010; Jeon et al., 2010;
Kim et al., 2012; Nishimoto et al., 2005). Due to the existence
of CD137L reverse signaling, which plays a critical role in the
immune response (Jeon et al., 2010; Kang et al., 2017; Lang-
stein et al., 1998; Schwarz, 2005; Kim et al., 2012), findings
regarding the functions of CD137 should be interpreted with
a degree of caution. Indeed, CD137 and CD137L are likely to
have coevolved to fulfill the same purpose (Kwon, 2012): their
bidirectional signaling pathways cooperate in multiple phases
of the immune response, including acute inflammation, inflam-
mation resolution, and even the dysregulation of chronic inflam-
mation (Eun et al., 2015; Jeon et al., 2010; Kang et al., 2017;
Mak et al., 2019). Given this, the spatiotemporal pairing of
CD137- or CD137L-expressing cells should be finely tuned dur-
ing each step of an inflammatory process. Interestingly, the
CD137-CD137L system functions as an immune checkpoint
at the phase of dendritic cell (DC) differentiation (Lee et al.,
2008, 2012; Kang et al., 2017; Kwon, 2018). For example,
CD137 signaling triggers the production of retinoic acid (RA)
by CD103+ DCs in the gut-associated lymphoid organs, which,
in turn, generates inducible Foxp3+ regulatory T (iTreg) cells
(Lee et al., 2012). On the other hand, CD137L signaling creates
an anti-inflammatory environment within tumors by inhibiting
the differentiation of interleukin (IL)-12-producing CD103+ DCs
while promoting that of CD11b+ DCs (Kang et al., 2017). How-
ever, little is known regarding how CD137 signaling in DCs reg-
ulates acute inflammation.
DCsplay a pivotal role inmaintaining intestinal homeostasis and
curbing the inflammation caused by the multilayered disruption of
intestinal homeostasis. The conventional DCs found in the intes-
tine can be broadly divided into two major subsets: CD103+
cDC1s and CD11b+ cDC2s (Guilliams et al., 2014). The cDC2s
canbe further classified intoCD103+ andCD103 fractions,which
dominate in the small intestine and the colon, respectively (Bogu-
novic et al., 2009; Satpathy et al., 2013). The diversification ofDCs,
which isdeterminedduring thecommonDCprogenitorstage in the
bonemarrow (Grajales-Reyesetal., 2015;Schlitzer etal., 2015),al-
lows for specialization in effective immunity and tolerance. For
example, CD103+ cDCs are required for the inductions of T helper
1 (TH1) and Tregcells,whereasCD11b
+ cDCsare critical for the in-
duction of TH2 cells, TH17 cells, and T follicular helper (TFH) cells
(Durai and Murphy, 2016). Although the functional dichotomy is
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less well understood in intestinal DCs, it is thought that intestinal
CD103+ cDC1s and intestinal CD11b+CD103+ DC2s are preferen-
tially required for the differentiation of Treg cells and TH17 cells,
respectively (Joeris et al., 2017).
Dextran sodium sulfate (DSS) is commonly used to induce
acute colitis in model animals (Kiesler et al., 2015; Eichele and
Kharbanda, 2017). A decade ago, DCs were shown to be posi-
tively or negatively involved in the development of DSS-induced
acute colitis (Abe et al., 2007; Berndt et al., 2007), but little is
known regarding how these processes are regulated. A recent
study demonstrated that p38a inhibits the TAK1-MKK4/7-JNK-
IL-27 axis in intestinal CD103+ DC1s and thereby decreases
the generation of type 1 Treg (Tr1) cells and type 3 innate
lymphoid cells (ILC3s) (Zheng et al., 2018). p38a-deficient
DC1s direct the differentiation of Tr1 cells and ILC3s via IL-27
production; the respective products of these cells, IL-10 and
IL-22, subsequently restrict intestinal inflammation and restore
epithelial barrier function, respectively (Zheng et al., 2018).
In the present study, we report that TAK1 acts as a divergence
point for CD137 signaling in intestinal CD103+ cDCs to regulate
acute colitis. It does so by increasing the survival of these cells
on one hand and by giving them a tolerogenic capacity through
induction of RALDH2 expression on the other hand. The TAK1-
AMPK axis stimulates the nuclear translocation of PGC-1a to
induce RALDH2 expression; thereafter, RA mediates two impor-
tant regulatory functions; namely, the generation of Treg cells
and the suppression of IL-23 production by CD11b+CD103
DCs via induction of SOCS3. Taken together, our results identify
CD137 as an immune checkpoint for acute colitis, which has
therapeutic implications for inflammatory bowel disease.
RESULTS
CD137/MiceExhibit Increased Susceptibility to Acute
Colitis
Colitis is known to be uncontrollable in CD137/ mice (Martı́nez
Gómez et al., 2013), but the mechanism underlying this process
remains to be clarified. In our experiments, mice were given 2%
DSS in the drinking water ad libitum for 9 days. There was a pro-
gressive body weight loss from day 5 to day 9 in both wild-type
(WT; CD137+/+) and CD137/ mice, with a significantly greater
reduction rate seen in CD137/ mice (Figure 1A). Consistently,
CD137/ mice exhibited greater shortening of the colon length
(Figure 1B). Histological and immunohistochemical analyses
demonstrated more distinguishable differences, including more
severe inflammation and tissue damage with loss of epithelial
crypts, in CD137/ mice compared to WT mice (Figures 1C–
1E). Interestingly, however, there was no difference in the severity
of colitis in CD137L+/+ versus CD137L/ mice (Figure S1).
CD137/ Mice Have a Decreased Frequency of
Intestinal CD11bCD103+ DCs and Foxp3+ Treg Cells
during Acute Colitis
To define characteristic changes in the intestine of CD137/
mice, we analyzed the composition of intestinal immune cells
in the lamina propria (LP) and mesenteric lymph nodes (MLNs)
on day 9. By adopting a strict gating strategy for the CD45+ LP
leukocyte pool, we identified CD11b+Ly6G+ cells as neutrophils
and Ly6GCD11b+F4/80+ cells as macrophages. After further
excluding CD11b+Ly6Chi monocytes, we gated CD11c+MHCII+
from the remaining cells as DCs (Figure S2A). The obtained
DCs were subdivided into four groups based on the expression
of CD11b and/or CD103 (Figure S2A). We further defined
CD11b+Ly6Chi monocytes as CX3CR1intMHCIIloCCR2hi cells
and CD11b+F4/80+ macrophages as CX3CR1hiMHCII+CCR2lo
cells (Figure S2B). Unlike DCs, macrophages expressed CD64
(Figure S2B) and showed a higher phagocytic activity (Fig-
ure S2C), confirming that the purified CD11b+CD103 DCs
were genuine DCs. Surprisingly, WT and CD137/ mice had
no difference in the frequency of neutrophils, macrophages,
monocytes, or DCs among the CD45+ leukocytes of the LP (Fig-
ure S2D). We also observed the same pattern of immune cell
composition in the MLNs (Figure S2E). However, there was a
lower frequency of CD11bCD103+ DC subsets among the
CD45+ leukocyte populations in the LP and MLNs of CD137/
mice versus WT mice, with the opposite pattern seen for
CD11b+CD103 DCs (Figures 2A and 2B). In a steady state,
there was no difference in the frequency of DC subsets in the
LP of WT versus CD137/ mice (Figure S3A). In addition, WT
and CD137/ mice had no quantitative difference in the fre-
quency of LP pre-DCs or that of DC progenitors in the bone
marrow (BM) (Figures S3B and S3C). These results indicate
that CD137 signaling played a major role in the process of DC
maturation toward CD11bCD103+ DCs during acute colitis.
We observed a lower activity of retinaldehyde dehydrogenase
2 (RALDH2, an enzyme involved in the production of RA inDCs) in
CD137/ LPandMLNCD11bCD103+DCs (Figures 2Cand2D)
but not in CD11b+CD103 DCs (Figures 2E and 2F). Consistent
with previous studies (Lee et al., 2012), CD137+CD11bCD103+
DCs exhibited higher RALDH2 activity (Figure 2G). There was
no difference in the RALDH2 activity of macrophages, another
major producer of RA (Broadhurst et al., 2012), in CD137/
versus WT LP and MLN CD11bCD103+ DCs (Figures S3D and
S3E). Another regulatory effector molecule produced by cDC1s
is IL-27, which regulates Tr1 differentiation (Zheng et al., 2018).
However, we did not observe any difference in intracellular levels
of IL-27 of intestinal CD11bCD103+ DCs between WT and
CD137/ mice (Figures S3F and S3G). As CD11bCD103+
DCs have the unique ability to induce Treg cells in the intestine
(Izcue et al., 2006; Sun et al., 2007), a reduction in their frequency
might be associated with a lower frequency of Treg cells and
more severe colitis. CD137/ mice had a higher number of
CD4+ T cells in the LP (Figure 2H) and an increased frequency
of these cells in MLNs (Figure 2I). Importantly, the frequency of
Treg cells was decreased in the LP and MLNs of CD137/
mice (Figure 2J), even though the percentage of LP and MLN
iTreg cells showed no difference between the two groups (Fig-
ure S3H). Taken together, our results suggest that quantitative
and qualitative changes in intestinal CD11bCD103+ DCs may
underlie the impaired ability of CD137/ mice to regulate intes-
tinal inflammation.
CD137 Signaling in DCs Is Critical for Regulating Acute
Colitis
Consistent with the observation that numerical and functional
changes of LP and MLN CD11bCD103+ DCs were a
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distinguishable feature of CD137/ mice with acute colitis,
CD137 expression in LP CD11bCD103+ DCs was the most
prominent, and its upregulation was also marked during colitis
in this subset (Figures 3A and 3B). We next explored whether
the disease phenotype observed inCD137/mice would be re-
produced in CD11cCreCD137fl/fl mice. We included CD137fl/fl
and Lyz2CreCD137fl/fl mice as controls. CD137 expression was
confirmed to be markedly reduced in DCs and macrophages
of CD11cCreCD137fl/fl and Lyz2CreCD137fl/fl, respectively (Fig-
ures S4A–S4D). CD11cCreCD137fl/fl mice exhibited greater de-
grees of body weight loss and colon shortening compared to
those in both control groups (Figures 3C and 3D). Histological
and immunohistochemical analyses demonstrated additional
differences, including increased severity of intestinal inflamma-
tion and tissue damage with loss of epithelial crypts in
CD11cCreCD137fl/fl mice (Figures 3E and 3F). More importantly,
the percentages of LP and MLN CD11bCD103+ DCs were
lower in CD11cCreCD137fl/fl mice versus CD137fl/fl mice (Figures
3G and 3H). It has been reported that CCR7 is critically important
in LP DCs for migration to MLNs (Jang et al., 2006). However,
CD137 signaling did not seem to be involved in the migration
of DCs to the LP, as their cell surface levels of CCR7 were not
different between CD11cCreCD137fl/fl and CD137fl/fl mice (Fig-
ures S4E and S4F). Our findings clearly indicate that CD137
signaling in DCs is associated with the maintenance of LP and
MLN CD11bCD103+ DCs during acute colitis, which is linked
to the proper control of colon inflammation.
CD137 Signaling Regulates the Survival of
CD11bCD103+ DCs through TAK1
The epithelial disruption induced by DSS allows Gram-negative
bacteria to enter the LP and exacerbates colon inflammation (Fig-
ure S5A). Tomimic the in vivo colitis condition in an in vitro system,
we examined CD137 signaling in mature CD11bCD103+ DCs in
Figure 1. CD137 Deficiency Promotes Acute Colitis
(A) Body weight changes of CD137+/+ (noncolitic, n = 10), CD137/ (noncolitic, n = 10), CD137+/+ (colitic, n = 10), and CD137/ (colitic, n = 10) mice. Data were
presented as mean ± SEM. ***p < 0.001 (Student’s t test).
(B) Colon length of CD137+/+ (noncolitic, n = 13), CD137/ (noncolitic, n = 15), CD137+/+ (colitic, n = 13), and CD137/ (colitic, n = 14) mice. ***p < 0.001
(Student’s t test).
(C) Representative microscopic images of H&E-stained colon sections of CD137+/+ (noncolitic), CD137/ (noncolitic), CD137+/+ (colitic), and CD137/ (colitic)
mice. Scale bars, 100 mm.
(D) Crypt damage scores of CD137+/+ (noncolitic, n = 8), CD137/ (noncolitic, n = 8), CD137+/+ (colitic, n = 8), and CD137/ (colitic, n = 8) mice. ***p < 0.001
(Student’s t test).
(E) Representative microscopic images of immunofluorescence-stained colon sections of CD137+/+ (noncolitic), CD137/ (noncolitic), CD137+/+ (colitic), and
CD137/ (colitic) mice. Scale bars, 100 mm. ***p < 0.001 (Student’s t test).
See also Figure S1.
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the presence of E. coli lipopolysaccharide (LPS). BM-derived DCs
(BMDCs) were generated from BM cells in the presence of Fms-
related tyrosine kinase ligand (Flt3L) for 9 days, and
CD11bCD103+ DC polarization was induced by adding inter-
feron gamma (IFN-g) and granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) for 2 days (Tussiwand et al., 2012; Kang
et al., 2017). Approximately 80% of cells were polarized to
CD11bCD103+ subsets after IFN-g and GM-CSF stimulation.
However, LPS treatment reduced the portion of CD11bCD103+
cells only in CD137/ DC culture (Figure 4A; Figure S5B), and
the percentages of CD11b+CD103 cells were comparable be-
tween WT and CD137/ cells (Figures S5B and S5C). This was
due to increased apoptosis specific for these cells (Figure 4B).
In addition, blocking the CD137 signal transduction pathway
with anti-CD137L antibody also induced a reduction in WT
CD11bCD103+ DC portions (Figure S5D) and in their Bcl-2 tran-
scription (Figure S5E). These results may explain the reduction in
CD103+ DCs in colitic CD137/ mice and human patients with
Crohn’s disease (Strauch et al., 2010; Magnusson et al., 2016).
Previous studies have demonstrated that CD137 signaling
serves as a survival factor in DCs by increasing expression of
the anti-apoptotic molecules Bcl-2 and Bcl-xL (Choi et al.,
2009). In our in vitro experimental system, LPS augmented
expression of not only CD137 but also Bcl-2 and Bcl-xL in WT
CD11bCD103+ DCs, but inhibition of CD137 signaling by either
genetic deletion of CD137 or anti-CD137L antibody failed to
enhance expression of Bcl-2 and Bcl-xL in these DCs (Figures
4C–4F; Figure S5E). Consistently, LPS induced the phosphoryla-
tion of the p65 subunit of nuclear factor kB (NF-kB) in WT
CD11bCD103+ DCs while decreasing cleavage of caspase 9
(Figure 4F). Related to this, we found that the engagement of
CD137 with an anti-CD137 agonist (3E1) was particularly effec-
tive in modulating the LPS-mediated upregulation of Bcl-2 and
Bcl-xL and the inhibition of caspase-9 cleavage in WT DCs but
not in CD137/ CD11b-CD103+ DCs (Figures 4G and 4H).
Notably, the levels of Bcl-2 and cleaved caspase-9 were not
influenced by LPS in either WT or CD137/ CD11b+CD103
DCs (Figures S5F–S5H). We also confirmed that the protein
levels of Bcl-2 and Bcl-xL were decreased and that those
of cleaved caspase-9 were increased in CD11cCreCD137fl/fl
LP and MLN CD11bCD103+ DCs after colitis induction (Figures
4I–4L).
TAK1 has been shown to be critical for the regulatory activity of
DCs (Zheng et al., 2018). Stimulation of CD137 in
CD11bCD103+ DCs induced phosphorylation of TAK1, but
this did not occur in CD11bCD103+ DCs pretreated with a
TAK1 inhibitor (Figures 4M and 4N). Importantly, this inhibitor
abolished the LPS-mediated increase in Bcl-2 expression and
decrease in cleaved caspase-9 in WT DCs but not in
CD137/ CD11bCD103+ DCs (Figure 4O). Taken together,
our results suggest that CD137 signaling in CD11bCD103+
DCs specifically regulates their maturation and survival during
intestinal inflammation in both transcription-dependent and -in-
dependent manners.
The TAK1-AMPK-PGC1a Axis Is Required for the
Production of RA by CD137 Signaling
We hypothesized that CD137 signaling results in RA production
via TAK1 in CD11bCD103+ DCs. Indeed, our experiments
showed that CD137 stimulation increased the expression of
Aldh1a2 (encoding RALDH2 enzyme) in WT but not in
CD137/ CD11bCD103+ DCs (Figure 5A). Since AMPK is a
kinase downstream of TAK1, we also examined its involvement
in CD137 signaling. As expected, stimulation of CD137 with an
anti-CD137 antibody increased the phosphorylation level of
AMPK and the expression of RALDH2 (Figure 5B). However,
TAK1 inhibition completely abrogated the effect of this anti-
CD137 antibody (Figure 5B). These results further confirmed
that TAK1 is involved in the expression of RALDH2 after
CD137 stimulation in CD11bCD103+ DCs.
PGC-1a (encoded by Ppargc1a) is a coactivator of many tran-
scription factors; it acts as a substrate for AMPK (Jäger et al.,
2007), which also induces increased Ppargc1a expression (Lin
et al., 2005). Consistent with these observations, CD137 stimu-
lation triggered upregulation of Ppargc1a in CD11bCD103+
DCs (Figure 5C) and induced the translocation of the encoded
protein into the nucleus (Figure 5D). These activities were abol-
ished by TAK1 inhibition (Figures 5C and 5D).
As RA secreted by DCs has been reported to regulate multiple
aspects of immune responses (Manicassamy et al., 2009; Man-
icassamy and Pulendran, 2009), we next examined whether RA
has an immunosuppressive effect on CD11b+CD103 DCs.
BMDCs were polarized into CD11b+CD103 DCs following
2 days of supplementation with IL-23 and GM-CSF. Treatment
of these CD11b+CD103 DCs with RA increased SOCS3 at the
transcriptional and translational levels (Figures 5E and 5F).
Decreased phosphorylation of p38MAPK, which is a target of
SOCS3, was associated with the RA-mediated induction of
SOCS3 (Figure 5F). Consistently, RA inhibited IL-23 expression
and secretion by LPS-stimulated CD11b+CD103 DCs (Figures
Figure 2. CD137 Deficiency Decreases CD11bCD103+ DCs and Foxp3+ Treg Cells in Acute Colitis
(A and B) Flow-cytometric analysis for LP (A) and MLN (B) DCs of colitic CD137+/+ mice (n = 13 in LP; n = 12 in MLN) and CD137/ mice (n = 13 in LP; n = 12 in
MLN). **p < 0.01; ***p < 0.001 (Student’s t test).
(C and D) Flow-cytometric analysis for ALDEFLUOR staining of LP (C) and MLN (D) CD11bCD103+ DCs of colitic CD137+/+ (n = 8) and CD137/ mice (n = 8).
Data are presented as mean ± SEM. *p < 0.05; ***p < 0.001 (Student’s t test).
(E and F) Flow-cytometric analysis for ALDEFLUOR staining of LP (E) and MLN (F) CD11b+CD103 DCs of colitic CD137+/+ (n = 8) and CD137/ mice (n = 8).
(G) Flow-cytometric analysis for ALDEFLUOR staining in CD137+ or CD137 LPCD11bCD103+ DCs of coliticCD137+/+mice (n = 7). Data are presented asmean
± SEM. **p < 0.01; ***p < 0.001 (Student’s t test).
(H) Flow-cytometric analysis for LP CD4+ and CD8+ T cells of colitic CD137+/+ (n = 11) and CD137/ mice (n = 11). *p < 0.05 (Student’s t test).
(I) Flow-cytometric analysis for MLN CD4+ and CD8+ T cells of colitic CD137+/+ (n = 8) and CD137/ mice (n = 8). **p < 0.05 (Student’s t test).
(J) Flow-cytometric analysis for LP and MLN Foxp3+ Treg cells of colitic CD137+/+ (n = 11 in both LP and MLN) and CD137/ mice (n = 9 in LP; n = 14 in MLN).
*p < 0.05; ***p < 0.001 (Student’s t test).
See also Figures S2 and S3.
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5G–5I). Finally, to directly show that RA produced by
CD11bCD103+ DCs can suppress IL-23 production of
CD11b+CD103 DCs, we co-cultured these two cell types in
the Transwell system. CD11b+CD103 DCs were pretreated
with RA receptor antagonist and co-cultured with WT or
CD137/ CD11bCD103+ DCs under LPS stimulation. We
found that the RA receptor antagonist increased IL-23 produc-
tion of WT CD11b+CD103 DCs but that it did not induce such
an increase in the CD11bCD103+ DCs of CD137/ mice
(Figures 5J and 5K). Our results indicate that CD11bCD103+
DCs may suppress the immunostimulatory activity of
CD11b+CD103 DCs through RA.
CD137 Signaling in CD11bCD103+ DCs Inhibits the
Differentiation of TH17 Cells
CD11b+CD103 DCs are known to promote intestinal inflam-
mation by activating and inducingmucosal TH17 cell responses
through IL-23 (Schlitzer et al., 2013; Scott et al., 2015). Since
the frequency of intestinal CD11b+CD103 DCs was increased
in CD137/ mice with colitis (Figures 2A and 2B; Figures 3G
and 3H), we hypothesized that increased CD11b+CD103
DCs and decreased CD11bCD103+ DCs in the intestine would
cause hyper-activated TH17 cell responses in CD137
/ mice.
We observed a significantly higher number of effector CD4+
T cells in the LP of CD137/ mice (Figure 2H), and their
frequency was also greater in theMLNs (Figure 2I). More impor-
tantly, CD137/ LP CD11b+CD103 DCs produced signifi-
cantly higher levels of IL-23 (Figure 6A). To count TH17 cells
from the LP andMLNs, we subjected CD3+CD4+ T cells to intra-
cellular staining for IL-17 (Figure S6). The absolute number of
TH17 cells was significantly increased in the CD137
/ LP (Fig-
ure 6B), and so was their frequency in total T cells (Figures 6C
and 6D). Increased percentages of TH17 cells in the T cell
population were also found in the LP and MLNs of
CD11cCreCD137fl/fl mice (Figures 6E and 6F). In aggregate,
the data presented so far indicate that RA may be a major
effector for CD137 signaling to suppress CD11b+CD103
DCs in the inhibition of TH17-mediated colitis. Indeed,
administration of RA had a protective effect on colitis in
CD11cCreCD137fl/fl mice (Figures 6G and 6H). RA adminis-
tration also ameliorated colitis in CD137fl/fl mice, but its
effect seemed to be less prominent compared to that
in CD11cCreCD137fl/fl mice (Figures 6G and 6H). This protec-
tion was correlated with decreased percentages of
IL-23+CD11b+CD103 DCs and TH17 cells in the LP and
MLNs of CD11cCreCD137fl/fl mice (Figures 6I and 6J).
CD137 Stimulation Attenuates the Severity of Acute
Colitis
As anti-CD137 agonistic antibodies are known to have therapeu-
tic effects on colitis (Lee et al., 2005), we examined whether
these effects arise from the stimulation of CD137 in
CD11bCD103+ DCs. Multiple injections of anti-CD137 antibody
starting from day1 of DSS treatment were found to protect the
host against DSS-induced colitis (Figures 7A–7E). This protec-
tion was associated with increased Bcl-2 expression and
RALDH2 activity in LP and MLN CD11bCD103+ DCs (Figures
S7A–S7C) but not in CD11b+CD103 DCs (data not shown).
Although the anti-CD137 antibody seemed to have a complex ef-
fect on the frequency of intestinal DC subsets (Figure S7D), its
protective effect was not observed in CD11cCreCD137fl/fl mice
(Figures 7F and 7G). As therewas no difference in CD4+ T cell po-
larization between CD11cCreCD137fl/fl and CD137fl/fl mice, and
anti-CD137 antibody did not affect this process in both groups
(Figure S7E), DCs, but not CD4+ T cells, were likely to be neces-
sary for its therapeutic effect on colitis.
DISCUSSION
Although immature DCs are well known to have a tolerogenic ac-
tivity for immunity (LutzandSchuler, 2002;SteinmanandNussenz-
weig, 2002), it is unclear howmature DCs control inflammation. In
this study, usingDC-specificCD137/mice,we identifiedCD137
as an immunosuppressive signal that regulates tolerogenic
CD11bCD103+ DCs during acute intestinal inflammation. Our
in vitro and in vivo results indicated that CD137 signaling is associ-
ated with three aspects of DC function: maturation, survival, and
immunosuppression. These CD137-associated functions seem
to be restricted mainly to intestinal CD11bCD103+ DCs. We do
not knowprecisely whyCD137 signaling is specific for this subset,
but we can suggest several possible explanations. A unique intes-
tinal microenvironment exposed to commensal microbiota and
foodantigens is likely to primeCD11bCD103+ topreferentially in-
crease CD137 expression in response to inflammatory mediators.
Onceexpressed,CD137deliverssignals thatenforce immunosup-
pressive activities andmediate cell maturation and survival. In this
case, homotypic cell-cell interactions seem to be sufficient to
engage CD137 (Figure 4). Interestingly, a previous study showed
that, within tumors, CD137L signaling is critical for the differentia-
tion of immunosuppressive CD11b+CD103 DC2s, and its
blockade promotes the differentiation of IL-12-producing
CD103+ DC1s (Kang et al., 2017). In the intestine, however, our re-
sults demonstrated that CD137 signaling is required for the
Figure 3. DC-Specific CD137 Deficiency Exacerbates Acute Colitis
(A) Representative fluorescence-activated cell sorting (FACS) histograms for CD137 expression in LP DC subsets of noncolitic or colitic CD137+/+ mice.
(B) Flow-cytometric analysis of CD137 expression in LP DC subsets of noncolitic (n = 4) or coliticCD137+/+mice (n = 4). Data are presented asmean ±SEM. ***p <
0.001 (Student’s t test).
(C) Body weight changes of coliticCD137fl/fl (n = 9), Lyz2CreCD137fl/fl (n = 9), andCD11cCreCD137fl/fl (n = 9) mice. Data are presented asmean ± SEM. ***p < 0.001
(Student’s t test).
(D) Colon length of colitic CD137fl/fl (n = 9), Lyz2CreCD137fl/fl (n = 9), and CD11cCreCD137fl/fl (n = 9) mice. **p < 0.01 (Student’s t test).
(E) Representative microscopic images of H&E-stained colon sections of colitic CD137fl/fl, Lyz2CreCD137fl/fl, and CD11cCreCD137fl/fl mice. Scale bars, 100 mm.
(F) Crypt damage scores of colitic CD137fl/fl (n = 9), Lyz2CreCD137fl/fl (n = 12), and CD11cCreCD137fl/fl (n = 11) mice. ***p < 0.001 (Student’s t test).
(G and H) Flow-cytometric analysis for LP (G) and MLN (H) DCs of CD137fl/fl (n = 8 in LP; n = 7 in MLN) and CD11cCreCD137fl/fl mice (n = 7 in LP; n = 9 in MLN).
*p < 0.05; ***p < 0.001 (Student’s t test).
See also Figure S4.
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Figure 4. CD137 Deficiency Promotes
Apoptosis of CD11bCD103+ DCs
(A) Portions of polarized CD11bCD103+ DCs in
CD137+/+ and CD137/ BMDCs after stimulation
with LPS for 24 h. Data are presented as mean ±
SEM of three independent experiments. *p < 0.05
(Student’s t test).
(B) Representative FACS dot plots for propium
iodide (PI) and annexin V staining in polarized
CD11bCD103+ DCs of CD137+/+ (n = 4) and
CD137/BMDCs (n = 4) after stimulation with LPS
for 24 h.
(C and D) Analysis for expression of Tnfrsf9 mRNA
(C) and cell-surface CD137 protein (D) in CD137+/+
CD11bCD103+ BMDCs after stimulation with LPS
for the indicated time. Tnfrsf9 expression was
normalized toActb expression. Data are presented
as mean ± SEM of three independent experiments.
**p < 0.01; ***p < 0.001 (one-way ANOVA with
Bonferroni correction).
(E) Real-time PCR analysis for expression of Bcl-2
and Bcl-xL in CD137+/+ and CD137/
CD11bCD103+ BMDCs after stimulation with LPS
for 12 h. Data were normalized to Actb expression
and are presented as mean ± SEM of three inde-
pendent experiments. *p < 0.05; **p < 0.01 (Stu-
dent’s t test).
(F) Western blot analysis for Bcl-2, Bcl-xL, cas-
pase-9 (Cas 9), cleaved caspase-9 (c-Cas 9), and
phosphorylated NF-kB (p-NF-kB) in CD137+/+ and
CD137/ CD11bCD103+ BMDCs in response to
LPS for 24 h. Data were normalized to actin band
intensities and are presented as mean ± SEM of
three independent experiments. *p < 0.05;
**p < 0.01 (Student’s t test).
(G) Real-time PCR analysis for expression of Bcl-2
and Bcl-xL in CD137+/+ and CD137/
CD11bCD103+ BMDCs in response to rat IgG or
anti-CD137 antibody (3E1). Data were normalized
to Actb expression and are presented as mean ±
SEM of three independent experiments. *p < 0.05;
**p < 0.01 (Student’s t test).
(H) Western blot analysis for Bcl-2, Bcl-xL, Cas 9,
c-Cas 9, and p-NF-kB in CD137+/+ and CD137/
CD11bCD103+ BMDCs in response to rat IgG or
3E1 for 24 h. Data were normalized to actin band
intensities and are presented as mean ± SEM of
three independent experiments. *p < 0.05;
**p < 0.01 (Student’s t test).
(I and J) Flow-cytometric analysis for intracellular
Bcl-2 in LP (I) and MLN (J) CD11bCD103+ DCs of
colitic CD137fl/fl (n = 6) and CD11cCreCD137fl/fl
(n = 6) mice. Data are presented as mean ± SEM.
*p < 0.05 (Student’s t test).
(K and L) Flow-cytometric analysis for intracellular
Bcl-2 expression in LP (K) and MLN (L)
CD11bCD103+ DCs of coliticCD137fl/fl (n = 8) and
CD11cCreCD137fl/fl (n = 8) mice. Data are pre-
sented as mean ± SEM. *p < 0.05; **p < 0.01
(Student’s t test).
(M) Western blot analysis for TAK1 and p-TAK1 in
CD137+/+ and CD137/ CD11bCD103+ BMDCs
in response to 3E1 in the presence of 5Z-7-ox-
ozeaenol (TAK1 inhibitor; 0.5 mM; 2-h pretreat-
ment) for 8 h.
(legend continued on next page)
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CD11bCD103+ subset to suppress the activity of the pathogenic
IL-23-producingCD11b+CD103 subset during colitis. Our in vitro
results indicate that interactions between CD137 and CD137L on
LPS-activatedCD11bCD103+DCs shouldbecritical in triggering
CD137 signaling (Figure S4D) (Mbanwi et al., 2017). However,
CD137L/ andWTmice did not exhibit any difference in disease
(N) Western blot analysis for TAK1 and p-TAK1 in CD137+/+ and CD137/CD11bCD103+ BMDCs in response to 3E1 in the presence of various doses of 5Z-7-
oxozeaenol for 8 h.
(O) Western blot analysis for Bcl-2, Cas 9, and c-Cas 9 in CD137+/+ and CD137/ CD11bCD103+ BMDCs in the presence of 5Z-7-oxozeaenol (0.5 mM; 2-h
pretreatment) for 24 h. Data were normalized to actin band intensities and are presented as mean ± SEM of three independent experiments. *p < 0.05; **p < 0.01
(Student’s t test).
Figure 5. CD137 Signaling Promotes RA
Production via the TAK1-AMPK-PGC1a Axis
(A) Real-time PCR analysis for expression of
Adlh1a2 in CD137+/+ and CD137/
CD11bCD103+ BMDCs in response to 3E1 in the
presence of 5Z-7-oxozeaenol (0.5 mM; 2-h pre-
treatment) for 12 h. Data were normalized to Actb
expression and are presented as mean ± SEM of
three independent experiments. *p < 0.05; **p <
0.01 (Student’s t test).
(B) Western blot analysis for AMPK, phosphoy-
lated (p)-AMPK, and RALDH2 in CD137+/+ and
CD137/ CD11bCD103+ BMDCs in response to
3E1 in the presence of 5Z-7-oxozeaenol (0.5 mM;
2-h pretreatment) for 24 h. Data were normalized to
actin band intensities and are presented asmean ±
SEM of three independent experiments. *p < 0.05;
**p < 0.01 (Student’s t test).
(C) Real-time PCR analysis for expression of
Ppargc1a in CD137+/+ and CD137/
CD11bCD103+ BMDCs in response to 3E1 in the
presence of 5Z-7-oxozeaenol (0.5 mM; 2-h pre-
treatment) for 12 h. Data were normalized to Actb
expression and are presented as mean ± SEM of
three independent experiments. *p < 0.05 (Stu-
dent’s t test).
(D) Western blot analysis for nuclear and cytosolic
PGC-1a in CD137+/+ and CD137/
CD11bCD103+ BMDCs in response to 3E1 in the
presence of 5Z-7-oxozeaenol (0.5 mM; 2-h pre-
treatment) for 24 h. Data were normalized to lamin
B or actin band intensities and are presented as
mean ± SEM of three independent experiments.
*p < 0.05; **p < 0.01 (Student’s t test).
(E) Real-time PCR analysis for expression of Socs3
in CD137+/+ CD11b+CD103 BMDCs in response
to RA for 12 h. Data were normalized to Actb
expression and are presented as mean ± SEM of
three independent experiments. *p < 0.05;
**p < 0.01 (01 (one-way ANOVA with Bonferroni
correction).
(F) Western blot analysis for SOCS3, p38MAPK,
and p-p38MAPK in CD137+/+ CD11b+CD103
BMDCs in response to RA for 24 h. Data were
normalized to actin or p38MAPK band intensities
and are presented as mean ± SEM of three inde-
pendent experiments. *p < 0.05; **p < 0.01 (one-
way ANOVA test with Bonferroni correction).
(G–I) Analysis for Il23a mRNA (G) and secreted (H)
or intracellular (I) IL-23 protein of CD137+/+
CD11b+CD103 BMDCs in response to LPS in the
presence of RA for 12 h (G) or 24 h (H and I). Data
are presented as mean ± SEM of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t test).
(J and K) Analysis for secreted (J) or intracellular IL-23 (K) of CD137+/+ CD11b+CD103 BMDCs cocultured with CD137+/+ or CD137/ CD11bCD103+ BMDCs
in response to LPS in the presence of RAR antagonist (AGN 193109). Data are presented as mean ± SEM of three independent experiments. **p < 0.01; ***p <
0.001 (Student’s t test).
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severity in our colitis model (Figure S1), suggesting that there may
exist an as-yet-unidentified CD137L. Signaling through a CD137L
of thisnaturehasbeen implicated in the inductionof tumorgrowth-
associatedDC2 andM2macrophage differentiationwithin tumors
(Kang et al., 2017; Kwon, 2018). As CD137L/ mice have
increased IL-4-dependent immunoglobulin G1 (IgG1) antibody re-
sponses (unpublished data), it seems that there is a competition
between these two CD137 ligands for binding to CD137. It is
also noteworthy that immune dysregulation is observed only in
CD137/ mice, probably because of the absence of regulatory
CD137 signaling. This hypothesis is currently under investigation
in our laboratory.
The earliest signaling event after the engagement of CD137 is
the recruitment of TRAF1 and TRAF2 to the intracellular domain
ofCD137,which is thought tobe followedby thepolyubiquitination
of TRAF2 (Martinez-Forero et al., 2013). Our results showed that
TAK1, which is a substrate for TRAF2 ubiquitin ligase (Ea et al.,
2006), isphosphorylated inCD11bCD103+DCsafter theengage-
ment of CD137 and that it regulates the survival of these cells via
the upregulation of the NF-kB target genes Bcl-2 and Bcl-xL and
the decreased cleavage of caspase-9 (Figure 4). TAK1 was also
Figure 6. CD137 Deficiency Promotes the
Differentiation of TH17 Cells
(A) Flow-cytometric analysis for intracellular IL-23
in LP CD11b+CD103 DCs of colitic CD137+/+
(n = 8) and CD137/ mice (n = 8). Data are pre-
sented as mean ± SEM. ***p < 0.001 (Student’s t
test).
(B–D) Flow-cytometric analysis for numbers (B)
and percentages (C) of LP TH subsets in colitic
CD137+/+ (n = 11) and CD137/ (n = 11) mice and
MLN TH subsets (D) of coliticCD137
+/+ (n = 10) and
CD137/ (n = 9) mice. *p < 0.05; ***p < 0.001
(Student’s t test).
(E and F) Flow-cytometric analysis for LP (E) and
MLN (F) TH subsets of colitic CD137
fl/fl (n = 8 in LP;
n = 11 in MLN) and CD11ccreCD137fl/fl (n = 9 in LP;
n = 11 in MLN) mice. **p < 0.01; ***p < 0.001
(Student’s t test).
(G) Bodyweight changes of RA- or vehicle-injected
colitic CD137fl/fl (n = 6 each group), and
CD11cCreCD137fl/fl (n = 6 each group) mice.
***p < 0.05 (Student’s t test).
(H) Colon length of RA- or vehicle-injected
colitic CD137fl/fl (n = 6 each group) and
CD11cCreCD137fl/fl (n = 6 each group) mice. *p <
0.05; *p < 0.01 (Student’s t test).
(I) Flow-cytometric analysis of intracellular IL-23
production by LP and MLN CD11b+CD103 DCs
of colitic CD11cCreCD137fl/fl mice injected with
vehicle (n = 6 each group) or RA (n = 6 each group).
*p < 0.05 (Student’s t test).
(J) Flow-cytometric analysis for LP and MLN TH17
cells of CD11cCreCD137fl/fl mice injected with
vehicle (n = 6 each group) or RA (n = 6 each group).
*p < 0.05 (Student’s t test).
See also Figure S6.
found to be critical in regulating the immu-
nosuppressive activity of these cells
through activation of AMPK and its down-
stream signaling partner, PCG-1a. This
signaling axis is indispensable for the expression of RA, which, in
turn, increases SOCS3 expression in adjacent CD11b+CD103
DCs to suppress p38MAPK,which is required for IL-23 production
(Figure5).Given thecritical roleof IL-23 inpathogenicTH17cell dif-
ferentiation (Kobayashi et al., 2008; Kara et al., 2015), we propose
that the RA-mediated inhibition of CD11b+CD103 DC activity
may be an important stage of immune regulation in the intestine.
However,RA is likely to haveabroad rangeof immunosuppressive
activities against a variety of immune cells, either directly or via
Treg cells (Larange and Cheroutre, 2016). It is also generally
accepted that RA and other immunosuppressive mediators (e.g.,
kynurenines, IL-10, and IL-27) cross-regulate each other in auto-
crine and paracrine manners (Quintana et al., 2010).
Agonistic anti-CD137 antibodies have potent therapeutic
effects on various autoimmune and inflammatory diseases
(Seo et al., 2004; Lee and Croft, 2009). Accumulating evidence
suggests that anti-CD137-mediated immunosuppression is
operated by two distinguishable mechanisms: deletion of Teff
cells through activation of cell death pathways, including the
Fas pathway (Kim et al., 2005; Asai et al., 2007; Zhang and Mit-
tler, 2007) and anergy of pathogenic T cells (Foell et al., 2003).
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The interface of DCs and T cells is important for these twomech-
anisms (Foell et al., 2003; Zhang et al., 2010). Immunosuppres-
sive or tolerogenic DCs generated by CD137 signaling seem to
be heterogeneous; here, we propose that they can be broadly
classified into two groups, even though their phenotypes and
functions can overlap. In the first category of DCs, CD137
signaling contributes to the production of immunosuppressive
effector molecules, including kynurenines, RA, and cytokines
(e.g., IL-10 and IL-27). Intestinal CD11bCD103+ DCs are repre-
sentative of this category, but phenotypic diversity exists among
these cells in organs other than the intestine (Iberg et al., 2017).
The second category of DCs may be phenotypically heteroge-
neous, but they commonly induce the cell death of Teff cells via
stimulation of death receptors. Thus, these DCs are likely to ex-
press molecules related to cell death and exhaustion (e.g., FasL,
tumor necrosis factor alpha [TNF-a], PD-L1, PD-L2, perforins,
and granzymes) (Yogev et al., 2012; Zlotnikov-Klionsky et al.,
2015). In sum, our results and those of other groups suggest
that CD137 signaling induces different subsets of tolerogenic
DCs, depending on the context of the immune response(s)
(Zhang and Mittler, 2007; Zhang et al., 2010; Lee et al., 2012).
Previously, it was not knownwhyCD137/mice exhibit dysre-
gulated immune responses in some experimental settings (Kwon
et al., 2002). Our results may provide important insights into this
impaired immune regulation in CD137/ mice. We believe that a
large part of the immunosuppressive activities driven by the
engagement of CD137 (either by its natural ligand or by an anti-
CD137 antibody) ismediatedby tolerogenicDCs and that amicro-
environment in which an immune response occurs seems to be
critical in determining whether stimulatory DCs or tolerogenic
DCs are co-opted. Together, our results indicate that the CD137-
CD137L system is an important component of the immunosup-
pressive intestinal microenvironment.
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Figure 7. Activation of CD137 Signaling In-
hibits Acute Colitis
(A) An experimental scheme.
(B) Body weight changes of colitic CD137+/+ mice
injected with 3E1 (n = 9) or control IgG (n = 8). Data
are presented as mean ± SEM. ***p < 0.001 (Stu-
dent’s t test).
(C) Colon length of colitic CD137+/+ mice injected
with 3E1 (n = 9) or rat IgG (n = 8). *p < 0.05 (Stu-
dent’s t test).
(D) Representative images of H&E-stained colon
sections of 3E1- or rat IgG-injected colitic
CD137+/+ mice. Scale abrs, 100 mm.
(E) Scores for colonic tissue disruption of 3E1- or
rat IgG-injected colitic CD137+/+ mice (n = 8).
**p < 0.01 (Student’s t test).
(F) Body weight changes of colitic
CD11cCreCD137fl/fl mice injected with 3E1 (n = 8)
or rat IgG (n = 8).
(G) Colon length of colitic CD11cCreCD137fl/fl mice
injected with 3E1 (n = 8) or rat IgG (n = 8).
See also Figure S7.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
CD137-/- (Kwon et al., 2002) and CD137L/ (DeBenedette et al., 1999) mice were crossed with C57BL/6J mice, and CD137+/+ and
CD137L+/+ mice were generated as controls. CD137 (Tnfrsf9) floxed mice were generated from Tnfrs9tm1a (EUCOMM)Wtsi embryonic
stem cells purchased from the European mouse mutagenesis (EUCOMM) Programme. The targeted ES cell clone was injected
into 3.5-day blastocysts and transferred to the uteri of pseudopregnant foster mothers. Male chimeras were mated with C57BL/6
females to obtain germline transmission of the Tnfrsf9 floxed allele. Tnfrsf9fl/flmice were generated by crossing germline-transmitted
CD137tm1a/tm1a mice to Flp mice. To generate DC- and macrophage-specific CD137 deficient mice, CD137fl/fl mice were crossed
with CD11ccre or Lyz2cre mice. These mice had no abnormality in weight or hematological parameters. 6-8 weeks old male littermate
mice were used for in vivo experiments. Mice weremaintained in SPF condition of a 12-h light/dark cycle, 23 ± 2C room temperature
and 55 ± 10%humidity. All animal experiments were approved by the Institutional Animal Care andUseCommittees (IACUC) of Ewha
Womans University and followed National Research Council Guidelines.
METHOD DETAILS
Induction of colitis and treatment
Micewere allowed to drink 2% (wt/vol) DSS (molecular weight 36–50 kDa;MPBiomedicals) dissolved in sterilized tapwater to induce
colitis or normal sterilized tap water as control ad libitum for 9 d. To examine the effect of anti-CD137 antibody (3E1) on colitis, mice
were intraperitoneally injected with 3E1 (100 mg/mouse/time) on days1, 0, +2, +4, and +6 (on day 0, mice began to drink DSS-con-
taining water). Rat IgG was used as control.
Assessment of inflammation and histology
The severity of colitis was based on body weight loss and histopathology of the colon. Mice were weighed daily. Body weight loss
was calculated as the percentage of weight lost from the baseline body weight of day 0. All mice were sacrificed 9 d after the begin-
ning of DSS drinking and colons were harvested. Colons were divided longitudinally, swiss rolled, and fixed in 10% buffered neutral-
ized formalin. Fixed tissues were embedded in paraffin and standard H&E staining for 5-mm colon sections was performed for
histologic grading. The histological score was calculated, using a semiquantitative system for abnormalities associated with colonic
tissue disruption with 0, 1, 2, 3 and 4 corresponding to no inflammation, mild inflammation, moderate inflammation, severe inflam-
mation, and severe inflammation with necrosis, respectively (Dasgupta et al., 2014). Each histological quantification was performed
in a blinded manner.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Mouse: C57BL/6J The Jackson Laboratory JAX:664
Mouse: CD137fl/fl This paper
Mouse: CD11ccre Prof. Hyoung-Pyo Kim Yonsei University N/A
Mouse: Lyz2cre The Jackson Laboratory JAX:4781
Mouse: Flp Prof. Han-Woong Lee, Yonsei University N/A
Mouse: CD11ccreCD137fl/fl This paper N/A
Mouse: Lyz2creCD137fl/fl This paper N/A
Oligonucleotides
See Table S1 N/A
Software and Algorithms
FlowJo (version 10.0.7) FlowJo RRID:SCR_008520
ZEN 2012 (blue edition) Carl Zeiss RRID:SCR_013672
InStat (version 4.0) GraphPad http://www.graphpad.com/
scientific-software/instat
Imeage J Imeage J RRID:SCR_003070
Cell Reports 30, 4124–4136.e1–e5, March 24, 2020 e3
Isolation of primary cells
Intestinal LP cells were isolated, as previously described (Weigmann et al., 2007). Briefly, the intestines were removed and cut into 4-
to 5-cm pieces, and feces were cleared by holding the intestine with forceps and flushing it with a syringe filled with cold PBS. The
residual mesenteric fat tissues and Peyer’s patcheswere resected, and the intestine pieceswere opened longitudinally, cut into 1-cm
pieces, andwashed in ice-cold PBS. The pieces of intestine were incubated in 5mL of pre-digestion solution (5 mMEDTA, 1mMDTT
in 1X HBSS without Mg2+ or Ca2+) for 20 min at 37C in a 50 mL tube, under slow rotation (40 g) in a thermal incubator. The remaining
pieces were collected with a 100-mm cell strainer and incubated in fresh pre-digestion solution as described above. The above-
described rotation incubation disrupted the epithelial cells from the mucosa. The remaining pieces were collected with a 100-mm
cell strainer and minced with scissors into 1-mm pieces. The tissue was collected into a gentleMACS C tube [Miltenyi Biotec]
containing 5 mL of digestion solution [0.05 g of collagenase D (Roche), DNase I, 0.3 g of Dispase II (Roche) in 100 mL of 1X
HBSS with Mg2+ and Ca2+] and incubated at 37C for 30 min with a gentleMACS Dissociator (Miltenyi Biotec). Mouse spleens
and lymph nodes were digested in 400 U/mL of collagenase D in FACS buffer for 25 min at 37C on a shaker.
Immunohistochemistry
Colon tissues were fixed with 10% buffered neutralized formaldehyde and embedded in paraffin. 5-mm sections were obtained and
placed on slides. Deparaffinization and dehydration of slides were done by washing slides with a series of xylene and ethanol solu-
tion. The slides were labeled with unconjugated primary goat anti-mouse E-cadherin antibody (R&D Systems) and then with Alexa
594-conjugated secondary antibodies (Invitrogen). Digital immunostaining images were captured and analyzed using an LSM780
confocal microscope (Carl Zeiss).
BMDCs
To obtain BMDCs, BM cells were harvested from femurs and tibias. RBC lysis was performed, and the remaining cells (23 106 cells/
ml) were cultured in IMDMmedia (GIBCO) containing 200 ng/ml murine Flt3L (PeproTech) for 9 d (Kang et al., 2017). For the following
2 d, the DCs were induced to polarize toward CD11b+CD103- subsets by the addition of IL-23 (1 ng/ml; PeproTech) and GM-CSF
(10 ng/ml; PeproTech), or toward CD11b-CD103+ subsets by the addition of IFN-g (0.1 ng/ml; Sigma-Aldrich) and GM-CSF
(10 ng/ml) (Kang et al., 2017). For transwell co-culture experiments, CD11b+CD103- DCs were first seeded on the bottom of 6-trans-
well cell culture system and pretreated with or without AGN193109 (Tocris Bioscience), a high affinity RA receptor (RAR) antagonist,
and CD11b-CD103+ DCs were seeded onto the membrane of transwell cell culture inserts (pore size: 0.4 mm). After seeding, cells
were stimulated with LPS (200 ng/ml; Sigma Aldrich).
Phagocytosis assay
For the analysis of phagocytosis, single-cell suspensions of colonic LP cells were incubated with 0.5 mm of Fluoresbrite YG Micro-
spheres (Polysciences) for 70 min at 37C. The cells were then washed twice with cold PBS, labeled with monoclonal antibodies
against CD45, CD11c, MHC II, and CD11b, and analyzed by flow cytometry (BD LSRFortessa).
QUANTITATIVE REAL-TIME PCR
Total RNA was extracted with the TRIzol reagent (GIBCO) and cDNA was synthesized with a Superscript III First-Strand Synthesis
System (Invitrogen). Quantitative PCRwas performed using the StepOne Plus Real-Time PCRSystem (Applied Biosystems). Tomea-
sure the bacterial DNA in the LP, DNA was isolated from faecal samples using the QIAamp DNA stool mini kit (QIAGEN) according to
manufacturer’s instructions. The proportion of bacterial family and genera in faecal samples were determined by real-time PCR.
Quantification values were calculated by the DDCT method relative to total bacterial 16S rRNA amplicons (Huang et al., 2015).
Primers sequences are indicated in Table S1.
Western blot analysis
Lysates of CD11b+CD103- DCs and CD11b-CD103+ DCs were subjected to 4%–15% gradient gel electrophoresis and the resolved
proteins were transferred to PVDFmembranes (Bio-Rad). Themembranes were blocked for 1 h at room temperature in 5% skimmilk
or BSA (Bovine serum albumin) in 1X TBST, and then incubatedwith specific antibodies. The following antibodies were used for west-
ern blot analysis: Bcl-2 (C-21), Bcl-xL (H5), Actin (C-11), Lamin B (M20) (all from Santa Cruz Biotechnology), p-NF-kB, Caspase 9,
cleaved Caspase 9, phosphorylated AMPK (p-AMPK), AMPK (all from Cell Signaling), p-TAK1, TAK1, RALDH2, phosphorylated
p38MAPK (p-p38MAPK), p38MAPK (all from Thermo Fisher Scientific), SOCS3, PGC1a (both from Abcam). After washing with 1X
TBST, the appropriate HRP-conjugated secondary was added for 1 h at room temperature. The bandswere visualizedwith enhanced
chemiluminescence reagents (Ab Frontier).
ELISA
The culture supernatants were assayed for IL-23 protein according to the manufacturer’s instructions (R&D Systems). The cells were
stimulated with LPS (200 ng/ml; Sigma Aldrich) for 24 h. The concentration of IL-23 was determined using a standard curve obtained
with recombinant IL-23.
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Flow cytometry
Cells were incubatedwith an anti-CD16/32monoclonal antibody (BioLegend) to block the Fc receptors at 4C for 30min, stainedwith
specific antibodies against surfacemarkers in FACSbuffer (PBS containing 2%FBS) at 4C for 30min, andwashedwith FACS buffer.
Monitoring of apoptosis was performed by staining with anti-Annexin V antibody and PI (BD Biosciences). Cells negative for PI but
positive for anti-Annexin V antibody were defined as apoptotic cells. Intracellular cytokine staining was performed using a
fixation/permeabilization solution kit (BD Biosciences) or a Foxp3 staining buffer set (eBioscience). For T cell activation, cells were
incubated with cell activation cocktail with Brefeldin A (BioLegend) in 1640 RPMI medium for 5 h. Stained cells were acquired using
a BD LSRFortessa flow cytometer and analyzed with the FlowJo software (Tree Star).
T cell polarization assay
Naive CD4+ T cells from the spleen and lymph node of 8-to-10-wk old CD137fl/fl and CD11cCre CD137fl/fl mice were enriched using
CD4MACSbeads (130-104-453, Miltenyi Biotec) and transferred to a 96-well plate coatedwith anti-CD3 (5 mg/ml, eBioscience), anti-
CD28 (2 mg/ml, eBioscience), and anti-CD137 antibodies (10 mg/ml). Cells were cultured for 5 d in the following TH polarization
conditions: 10 ng/ml IL-2, 10 ng/ml IL-12, and 10 mg/ml anti-IL-4 antibody for TH1 cell polarization (CytoBox TH1, Miltenyi Biotec);
10 ng/mL IL-4, 10 ng/mL IL-2, 10 mg/mL and anti-IFN-g antibody for TH2 cell polarization (CytoBox TH2, Miltenyi Biotec); 20 ng/ml
IL-6, 10 ng/ml IL-23, 10 ng/ml IL-1b, 2 ng/ml human TGF-b1, 10 mg/ml anti-IL-4 antibody, 10 mg/ml anti-IFN-g antibody,
and10 mg/ml anti-IL-2 antibody for TH17 cell polarization (CytoBox TH17, Miltenyi Biotec). Harvested CD4
+ T cells were stimulated
for 5 h with cell activation cocktail with Brefeldin A (BioLegend) and intracellular cytokine staining was performed to detect intracel-
lular INF-g, IL-4, or IL-17A.
Statistical analysis
Unpaired Student’s t test and one-way ANOVA test were performed using the InStat (version 4.0) for Windows software package
(GraphPad). Shapiro–Wilk normality test was performed using the SPSS software. P values less than 0.05 were considered statisti-
cally significant.
DATA AND CODE AVAILABILITY
This study did not generate any datasets.
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Figure S1. CD137L-/- mice show a similar degree of colitis severity to WT mice, related to
Figure 1
(A) Body weight changes of CD137L+/+ (noncolitic, n = 4), CD137L-/- (noncolitic, n = 4), 
CD137L+/+ (colitic, n = 6), and CD137L-/- mice (colitic, n = 8). Data were presented as mean ±
SEM. 
(B) Colon length of CD137L+/+ (noncolitic, n = 4), CD137L-/- (noncolitic, n = 4), CD137L+/+ (colitic, 
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Figure S2. Analysis of myeloid cells in the LP and MLNs, related to Figure 2.
(A) Gating strategies of LP myeloid cell types.
(B) Flow cytometric analysis for cell surface marker expression of LP macrophages (red lines), Ly6chi
monocytes (blue lines), and DCs (green lines).
(C) Analysis for the phagocytic activities of LP macrophages and CD11b+CD103- DCs. Data were
presented as mean ± SEM of two independent experiments. ***P < 0.001 (Student’s t test).
(D and E) Flow cytometric analysis for the immune cell compositions in the LP (D) and MLNs (E) of






























































































































































































































































































































































































































Figure S3. FACS analysis of intestinal macrophages and DC subsets, and BM cDC
progenitors/precursors, related to Figure 2.
(A)Flow cytometric analysis for LP DC subsets of CD137+/+ (n = 6) and CD137-/- mice (n = 6).
(B) Flow cytometric analysis for BM pre-DCs of CD137+/+ (n = 6) and CD137-/- mice (n = 6).
(C) Flow cytometric analysis for BM DC progenitors of CD137+/+ (n = 6) and CD137-/- mice (n = 6).
(D and E) Flow cytometric analysis for ALDEFLUOR staining in LP (D) and MLN macrophages (E)
of colitic CD137+/+ (n = 8) and CD137-/- mice (n = 8). Data were presented as mean ± SEM.
(F and G) Flow cytometric analysis for intracellular IL-27 in LP (F) and MLN
CD3+CD4+Foxp3+Helios- inducible Treg (iTreg) cells (G) of colitic CD137+/+ (n = 6) and CD137-/-

































































































































































































































































Figure S4. FACS analysis of CD137 and CCR7 expression in intestinal DCs , related to Figure 3.
(A and B) Flow cytometric analysis for CD137 expression in LP DCs (A) and Treg cells (B) of
CD137fl/fl (n = 6 each group) and CD11ccreCD137fl/fl mice (n = 6 each group). Data were presented as
mean ± SEM. ***P < 0.001 (Student’s t test).
(C and D) Flow cytometric analysis for CD137 expression in LP macrophages (C) and Treg cells (D) of
CD137fl/fl (n = 6 each group) and LyzcreCD137fl/fl mice (n = 6 each group). Data were presented as mean
± SEM. ***P < 0.001 (Student’s t test).
(E and F) Flow cytometric analysis for CCR7 expression in LP CD11b+CD103- (E) and CD11b-CD103+
DCs (F) of CD137fl/fl (n = 6 each group) and CD11ccreCD137fl/fl mice (n = 6 each group). Data were
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Figure S5. Penetration of gut bacterial microbiota and effects of LPS on intestinal DC survival,
related to Figure 4.
(A) Analysis for bacterial penetration into the colon in CD137+/+ (noncolitic, n = 3), CD137-/-
(noncolitic, n = 3), CD137+/+ (colitic, n = 3), and CD137-/- mice (colitic, n =3). PCR analysis of 16S
rDNA. Data were presented as mean ± SEM. *P < 0.05 (Student’s t test).
(B) Representative FACS dot plots for polarized CD11b+CD103- and CD11b-CD103+ BMDCs gated
from CD45+F4/80-CD11c+MHCII+ cells.
(C) Portions of polarized CD11b+CD103- DCs in CD137+/+ and CD137-/- BMDCs after stimulation
with LPS for 24 h. Data were presented as mean ± SEM of three independent experiments.
(D) Portions of polarized CD11b-CD103+ DCs in CD137+/+ BMDCs after stimulation with LPS in the
presence of anti-CD137L antibody (TSK-1) for 24 h. Data were presented as mean ± SEM of three
independent experiments. *P < 0.05 (Student’s t test).
(E) RT-PCR analysis for Bcl-2 expression in of polarized CD137+/+ CD11b-CD103+ BMDCs after
stimulation with LPS in the presence of anti-CD137L antibody (TSK-1) for 12 h. Data were presented
as mean ± SEM of three independent experiments. *P < 0.05 (Student’s t test).
(F) Western blot analysis of Bcl-2, caspase 9, and cleaved Caspase 9 (c-Cas 9) in polarized CD137+/+
and CD137-/- CD11b+CD103- BMDCs after stimulated with LPS for 24 h.
(G and H) Flow cytometric analysis for intracellular Bcl-2 (G) and cleaved Caspase 9 (H) expression
in LP CD11b+CD103- DCs of colitic CD137fl/fl (n = 6) and colitic CD11ccreCD137fl/fl mice (n = 6).
Data were presented as mean ± SEM.
Figure S6. Gating strategies for T cell subsets, related to Figure 6.
After SSClow and FSClow dead cells, doublet cells, and autofluorescent cells were gated out, TH1
cells were gated as CD45+CD3+CD4+IFN-γ+, TH2 cells were gated as CD45
+CD3+CD4+IL-4+, and
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Figure S7. Injection of 3E1 increases Bcl-2 expression and RADH2 activities in intestinal
CD11b-CD103+ DCs, related to Figure 7.
(A and B) Flow cytometric analysis for intracellular Bcl-2 in LP (A) and MLN (B) CD1b-CD103+
DCs of colitic CD137+/+ mice injected with 3E1 (n = 9 in LP; n = 10 in MLN) or rat IgG (n = 9 in
LP; n = 10 in MLN). *P < 0.05; **P < 0.01 (Student’s t test).
(C) Flow cytometric analysis for ALDEFLUOR staining in LP and MLN CD11b-CD103+ DCs of
colitic CD137+/+ mice injected with 3E1 (n = 6 each group) or rat IgG (n = 6 each group). **P
< 0.01 (Student’s t test).
(D) Flow cytometric analysis for LP DC subsets of absolute numbers (left) and percentages (right)
of DC subsets of colitic CD137+/+ mice injected with 3E1 (n = 6) or rat IgG (n = 6). Data were
presented as mean ± SEM. *P < 0.05 (Student’s t test).
(E) Analysis for TH polarization of CD137
fl/fl and CD11cCreCD137fl/fl CD4+ T cells under TH
polarization conditions in the presence of 3E1 (n = 4 each group) or rat IgG (n = 4 each group) for
5 d. TH1, IFN-γ
+CD4+; TH2, IL-4
+CD4+; TH17, IL-17
+CD4+. Data were presented as mean ± SEM.
